The evolving face of heart failure management.

Background: Heart failure (HF) is a major cause of morbidity and mortality in Australia. While the therapeutic options available for HF remain limited, recent studies have expanded treatment options to include angiotensin-neprilysin inhibitors (ARNIs) and sodium-glucose co-transporter-2 (SGLT2) inhibitors.

Objective: The aim of this article is to provide an update on the management of HF for general practitioners (GPs), who play a pivotal part in the management of patients with complex presentations.